T. Rowe Price Associates
PGEN icon

T. Rowe Price Associates’s Precigen PGEN Stock Holding History

T. Rowe Price Associates’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$905K Buy
158,614
+19,438
+14% +$84K ﹤0.01% 2379
2026
Q1 		$539K Buy
139,176
+41,238
+42% +$169K ﹤0.01% 2418
2025
Q4 		$410K Buy
97,938
+18,382
+23% +$71.1K ﹤0.01% 2484
2025
Q3 		$262K Buy
79,556
+10,690
+16% +$30.2K ﹤0.01% 2674
2025
Q2 		$98K Buy
68,866
+8,600
+14% +$12.2K ﹤0.01% 2898
2025
Q1 		$90K Sell
60,266
-70,000
-54% -$110K ﹤0.01% 2843
2024
Q4 		$146K Sell
130,266
-39,235
-23% -$33.5K ﹤0.01% 2773
2024
Q3 		$161K Hold
169,501
– – ﹤0.01% 2723
2024
Q2 		$268K Buy
169,501
+4,349
+3% +$6.32K ﹤0.01% 2469
2024
Q1 		$240K Buy
165,152
+5,304
+3% +$7.62K ﹤0.01% 2535
2023
Q4 		$215K Hold
159,848
– – ﹤0.01% 2515
2023
Q3 		$227K Sell
159,848
-10,507
-6% -$14.9K ﹤0.01% 2457
2023
Q2 		$196K Sell
170,355
-20,100
-11% -$23.7K ﹤0.01% 2541
2023
Q1 		$202K Buy
190,455
+11,721
+7% +$16.9K ﹤0.01% 2526
2022
Q4 		$272K Hold
178,734
– – ﹤0.01% 2405
2022
Q3 		$379K Buy
178,734
+68,110
+62% +$144K ﹤0.01% 2267
2022
Q2 		$148K Buy
110,624
+36,358
+49% +$53.9K ﹤0.01% 2673
2022
Q1 		$157K Buy
74,266
+9,400
+14% +$22.9K ﹤0.01% 2762
2021
Q4 		$241K Buy
64,866
+44,100
+212% +$190K ﹤0.01% 2693
2021
Q3 		$104K Hold
20,766
– – ﹤0.01% 2839
2021
Q2 		$135K Buy
20,766
+3,351
+19% +$23.4K ﹤0.01% 2798
2021
Q1 		$120K Sell
17,415
-10,464
-38% -$88.5K ﹤0.01% 2769
2020
Q4 		$284K Sell
27,879
-24,300
-47% -$158K ﹤0.01% 2441
2020
Q3 		$183K Hold
52,179
– – ﹤0.01% 2439
2020
Q2 		$260K Sell
52,179
-6,704
-11% -$22.8K ﹤0.01% 2283
2020
Q1 		$200K Buy
58,883
+300
+0.5% +$1.29K ﹤0.01% 2318
2019
Q4 		$321K Buy
58,583
+2,795
+5% +$15.7K ﹤0.01% 2298
2019
Q3 		$319K Buy
55,788
+25,693
+85% +$175K ﹤0.01% 2261
2019
Q2 		$231K Buy
30,095
+200
+0.7% +$1.08K ﹤0.01% 2381
2019
Q1 		$157K Buy
29,895
+200
+0.7% +$1.39K ﹤0.01% 2433
2018
Q4 		$194K Buy
+29,695
New +$333K ﹤0.01% 2415
2017
Q4 		– Sell
-27,967
Closed -$532K – 2601
2017
Q3 		$532K Buy
27,967
+4,430
+19% +$91.2K ﹤0.01% 2070
2017
Q2 		$567K Sell
23,537
-397
-2% -$8.71K ﹤0.01% 2012
2017
Q1 		$474K Sell
23,934
-209
-0.9% -$4.67K ﹤0.01% 2086
2016
Q4 		$581K Sell
24,143
-5,550
-19% -$154K ﹤0.01% 1992
2016
Q3 		$825K Buy
29,693
+5,358
+22% +$142K ﹤0.01% 1815
2016
Q2 		$594K Buy
24,335
+15,639
+180% +$444K ﹤0.01% 1898
2016
Q1 		$292K Buy
+8,696
New +$274K ﹤0.01% 2165
2015
Q1 		– Sell
-399,071
Closed -$10.5M – 2566
2014
Q4 		$10.5M Sell
399,071
-1,361
-0.3% -$29.8K ﹤0.01% 1311
2014
Q3 		$7.11M Sell
400,432
-9,940
-2% -$203K ﹤0.01% 1393
2014
Q2 		$9.86M Sell
410,372
-5,127
-1% -$104K ﹤0.01% 1323
2014
Q1 		$10.4M Sell
415,499
-15,904
-4% -$440K ﹤0.01% 1287
2013
Q4 		$9.81M Buy
431,403
+837
+0.2% +$16.9K ﹤0.01% 1289
2013
Q3 		$9.75M Buy
+430,566
New +$9.94M ﹤0.01% 1279

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's PGEN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Precigen (PGEN) stake by 14% in Q2 2026, buying an estimated $84K and bringing the position to 158,614 shares worth $905K. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

T. Rowe Price Associates first reported a position in PGEN in Q3 2013 and has held it in 44 quarters since. The position peaked at $10.5M in Q4 2014. 211 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

  • T. Rowe Price Associates held 158,614 shares of Precigen worth $905K as of Q2 2026.
  • T. Rowe Price Associates bought 19,438 Precigen shares in Q2 2026, an estimated $84K.
  • Precigen made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2379 holding.
  • T. Rowe Price Associates first reported a position in Precigen in Q3 2013 and has held it in 44 quarters since.
  • T. Rowe Price Associates's Precigen position peaked at $10.5M in Q4 2014.
  • 211 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.